<DOC>
	<DOC>NCT02245464</DOC>
	<brief_summary>The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years</brief_summary>
	<brief_title>Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Male and female patients diagnosed with essential hypertension Patients without prior experience with Micardis tablet Known hypersensitivity to Micardis tablet Pregnancy or breastfeeding Biliary atresia Severe hepatic failure patients Severe renal failure patients</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>